Surface Logix, Inc.
Surface Logix creates new drugs by tweaking the pharmacokinetic and pharmacodynamic properties of existing drugs and new compounds. Its Pharmacomer Technology improves a drug's solubility and permeability in the body and reduce side effects. It has a pipeline of pre-clinical and clinical candidates in development for treatment of metabolic diseases and hypertension. Its drug candidate SLx-4090 is in clinical trials to test its ability to lower blood lipid levels, reduce triglyceride uptake, and block absorption of other fats. Its SLx-2101 candidate is being investigated for treatment of hypertension and Raynaud's Syndrome.
Contact Details
Office Address
Surface Logix, Inc.
50 Soldiers Field Place
Brighton, MA, USA 02135
Phone: (617) 746-8500
Fax: (617) 783-8877
Executives
Chairman
Steven Gillis
President, CEO, and Director
Keith Dionne